Culture of stem cells that can be propagated indefinitely
A stem cell line is a group of stem cells that is cultured in vitro and can be propagated indefinitely. Stem cell lines are derived from either animal or human tissues and come from one of three sources: embryonic stem cells, adult stem cells, or induced stem cells. They are commonly used in research and regenerative medicine.
By definition, stem cells possess two properties can be mine.: (1) they can self-renew, which means that they can divide indefinitely while remaining in an undifferentiated state; and (2) they are pluripotent or multipotent, which means that they can differentiate to form specialized cell types. Due to the self-renewal capacity of stem cells, a stem cell line can be cultured in vitro indefinitely.
A stem-cell line is distinctly different from an immortalized cell line, such as the HeLa line. While stem cells can propagate indefinitely in culture due to their inherent properties, immortalized cells would not normally divide indefinitely but have gained this ability due to mutation. Immortalized cell lines can be generated from cells isolated from tumors, or mutations can be introduced to make the cells immortal.[1]
A stem cell line is also distinct from primary cells. Primary cells are cells that have been isolated and then used immediately. Primary cells cannot divide indefinitely and thus cannot be cultured for long periods of time in vitro.[citation needed]
An embryonic stem cell line is created from cells derived from the inner cell mass of a blastocyst, an early stage, pre-implantation embryo.[2] In humans, the blastocyst stage occurs 45 days post fertilization. To create an embryonic stem cell line, the inner cell-mass is removed from the blastocyst, separated from the trophoectoderm, and cultured on a layer of supportive cells in vitro. In the derivation of human embryonic stem cell lines, embryos left over from in vitro fertilization (IVF) procedures are used. The fact that the blastocyst is destroyed during the process has raised controversy and ethical concerns.
Embryonic stem cells are pluripotent, meaning they can differentiate to form all cell types in the body. In vitro, embryonic stem cells can be cultured under defined conditions to keep them in their pluripotent state, or they can be stimulated with biochemical and physical cues to differentiate them to different cell types.
Adult stem cells are found in juvenile or adult tissues. Adult stem cells are multipotent: they can generate a limited number of differentiated cell types (unlike pluripotent embryonic stem cells). Types of adult stem cells include hematopoietic stem cells and mesenchymal stem cells. Hematopoetic stem cells are found in the bone marrow and generate all cells of the immune system all blood cell types. Mesenchymal stem cells are found in umbilical cord blood, amniotic fluid, and adipose tissue and can generate a number of cell types, including osteoblasts, chondrocytes, and adipocytes. In medicine, adult stem cells are mostly commonly used in bone marrow transplants to treat many bone and blood cancers as well as some autoimmune diseases.[3] (See Hematopoietic stem cell transplantation)
Of the types of adult stem cells have successfully been isolated and identified, only mesenchymal stem cells can successfully be grown in culture for long periods of time. Other adult stem cell types, such as hematopoietic stem cells, are difficult to grow and propagate in vitro.[4] Identifying methods for maintaining hematopoietic stem cells in vitro is an active area of research. Thus, while mesenchymal stem cell lines exist, other types of adult stem cells that are grown in vitro can better be classified as primary cells.
Induced pluripotent stem cell (iPSC) lines are pluripotent stem cells that have been generated from adult/somatic cells. The method of generating iPSCs was developed by Shinya Yamanaka's lab in 2006; his group demonstrated that the introduction of four specific genes could induce somatic cells to revert to a pluripotent stem cell state.[5]
Compared to embryonic stem-cell lines, iPSC lines are also pluripotent in nature but can be derived without the use of human embryosa process that has raised ethical concerns. Furthermore, patient-specific iPSC cell lines can be generatedthat is, cell lines that are genetically matched to an individual. Patient-specific iPSC lines have been generated for the purposes of studying diseases[6] and for developing patient-specific medical therapies.
Stem-cell lines are grown and maintained at specific temperature and atmospheric conditions (37 degrees Celsius and 5% CO2) in incubators. Culture conditions such as the cell growth medium and surface on which cells are grown vary widely depending on the specific stem cell line. Different biochemical factors can be added to the medium to control the cell phenotypefor example to keep stem cells in a pluripotent state or to differentiate them to a specific cell type.
Stem-cell lines are used in research and regenerative medicine. They can be used to study stem-cell biology and early human development. In the field of regenerative medicine, it has been proposed that stem cells be used in cell-based therapies to replace injured or diseased cells and tissues. Examples of conditions that researchers are working to develop stem-cell-based treatments for include neurodegenerative diseases, diabetes, and spinal cord injuries.
There is controversy associated with the derivation and use of human embryonic stem cell lines. This controversy stems from the fact that derivation of human embryonic stem cells requires the destruction of a blastocyst-stage, pre-implantation human embryo. There is a wide range of viewpoints regarding the moral consideration that blastocyst-stage human embryos should be given.[7][8]
In the United States, Executive Order 13505 established that federal money can be used for research in which approved human embryonic stem-cell (hESC) lines are used, but it cannot be used to derive new lines.[9] The National Institutes of Health (NIH) Guidelines on Human Stem Cell Research, effective July 7, 2009, implemented the Executive Order 13505 by establishing criteria which hESC lines must meet to be approved for funding.[10] The NIH Human Embryonic Stem Cell Registry can be accessed online and has updated information on cell lines eligible for NIH funding.[11] There are 378 approved lines as of March 2017.
Studies have found that approved hESC lines are not uniformly used in the US data from cell banks and surveys of researchers indicate that only a handful of the available hESC lines are routinely used in research. Access and utility are cited as the two primary factors influencing what hESC lines scientists choose to work with.[12]
A 2011 survey of stem cell scientists in the US who use hESC lines in their research found that 54% of respondents used two or fewer lines and 75% used three or fewer lines.[13]
Another study tracked cell-line requests fulfilled from the largest US repositories, the National Stem Cell Bank (NSCB) and the Harvard Stem Cell Institute (HSCI; Cambridge, MA, USA), for the periods March 1999 December 2008 (for NSCB) and April 2004 December 2008 (for HSCI).[14] For NSCB, out of twenty-one approved cell lines, 77% of requests were for two of the lines (H1 and H9). For HSCI, out of the 17 lines requested more than once, 24.7% of requests were for the two most commonly requested lines.
Read more here:
- Rapid and scalable personalized ASO screening in patient-derived organoids - Nature.com - January 23rd, 2025
- Multifactorial approach is needed to unravel the maturation phases of human neurons derived from induced pluripotent stem cells - Nature.com - January 21st, 2025
- Unlock the Potential of iPSC Differentiation with Creative Biolabs - EIN News - January 17th, 2025
- Automated iPS Cell Production to Start in Japan in April - Nippon.com - January 9th, 2025
- iPSCs: take the survey and win! - RegMedNet - January 9th, 2025
- Automated iPS cell production to start in Japan in April - The Japan Times - January 9th, 2025
- Dysregulation of mTOR signalling is a converging mechanism in lissencephaly - Nature.com - January 1st, 2025
- BrightPath-Cellistic partner for clinical trial advancements of CAR-T cell therapy - Yahoo Finance - December 17th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 15th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 13th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 7th, 2024
- What are Induced Pluripotent Stem Cells? | ISCRM - December 7th, 2024
- Induced pluripotent stem cells, a giant leap for mankind therapeutic ... - December 7th, 2024
- Advantages and disadvantages of induced pluripotent stem cells - December 7th, 2024
- Generation and long-term culture of human cerebellar organoids from pluripotent stem cells - Nature.com - December 3rd, 2024
- Whats the secret to living to 100? Centenarian stem cells could offer clues - Nature.com - December 1st, 2024
- Single-cell RNA sequencing reveals key regulators and differentiation trajectory of iPSC-derived cardiomyocytes - Nature.com - November 26th, 2024
- Cell therapy weekly: GMP certification of iPSC-focused manufacturing facility - RegMedNet - November 25th, 2024
- Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - Pharmaceutical Technology - November 22nd, 2024
- Alloy Therapeutics, Takeda Partner on Revolutionary iPSC Cell Therapy Platform | TAK Stock News - StockTitan - November 22nd, 2024
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections - The Japan News - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
Recent Comments